RT Journal Article
SR Electronic
T1 Real-time molecular classification of leukemias
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.22.22276550
DO 10.1101/2022.06.22.22276550
A1 Mélanie Sagniez
A1 Shawn M. Simpson
A1 Maxime Caron
A1 Marieke Rozendaal
A1 Bastien Paré
A1 Thomas Sontag
A1 Sylvie Langlois
A1 Alexandre Rouette
A1 Vincent-Philippe Lavallée
A1 Sonia Cellot
A1 Daniel Sinnett
A1 Thai Hoa Tran
A1 Martin A. Smith
YR 2022
UL http://medrxiv.org/content/early/2022/06/27/2022.06.22.22276550.abstract
AB Gene expression profiling provides a detailed molecular snapshot of cellular phenotypes that can be used to compare different biological conditions. Nanopore sequencing technology can generate high-resolution transcriptomic data in real-time and at low cost, which heralds new opportunities for molecular medicine. In this study, we demonstrate the clinical utility of real-time transcriptomic profiling by processing RNA sequencing data from childhood acute lymphoblastic leukemia (ALL) patients on-the-fly with a trained neural network classifier. This strategy successfully distinguished 11/12 representative ALL molecular subtypes and one non-leukemia control in as little as 5 minutes of sequencing on a MinION sequencer or in less than 1 hour on disposable, low cost Flongle flow cells. Our findings suggest that real-time transcriptomics constitutes a drastically efficient solution for the molecular diagnosis of ALL and other diseases, where conventional clinical workflows require days if not weeks to achieve similar results.Competing Interest StatementMAS, MS and BP have received financial travel support from Oxford Nanopore Technologies.Funding StatementThis work was partially funded by a Cole Foundation transition award, a Canadian Foundation for Innovation John R. Evans Leaders Fund (40767) and a National Science and Engineering Research Council of Canada Discovery Grant (RGPIN-2022-04265) to MAS. MS is partially supported by a Cole Foundation fellowship. BP is partially supported by a Fonds de Recherche du Quebec - Sante postdoctoral fellowship. MAS is partially supported by a Fonds de Recherche du Quebec - Sante, Junior 1 fellowship and establishment award (307539). We would also like to thank participating patients and their families, as well as the Fondation CHU Sainte-Justine for their global support. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Centre Hospitalier Universitaire Sainte-Justine Institutional Review Board (FWA00021692, designated by the Ministere de la Sante et des Services Sociaux du Quebec) gave ethical approval for this work (research protocol project code MP-21-2019-2032).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.